Monopar Therapeutics
Nasdaq · Healthcare · Pharmaceutical Preparations · Wilmette, IL
MNPR chart
What traders are saying about $MNPR
Latest postsMonopar Therapeutics news
- Monopar Therapeutics stock price prediction: Short-term downside risk with $63.8 support in focus
Traders Union ·
- Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
Yahoo Finance ·
- Monopar Therapeutics Inc. Presents Baseline Data And Long-Term Safety Data For ALXN1840 In Wilson Disease At AASLD ? The Liver Meeting 2026
www.marketscreener.com ·
- Form 4 Monopar Therapeutics Inc: Kim R. Tsuchimoto (Director) For: 2 November
Investing.com UK ·
- Monopar Therapeutics director Kim Tsuchimoto sells $290,061 in shares.
Investing.com ·
- Monopar Therapeutics director Raymond Anderson sells $214,746 stock
Investing.com ·
- A director exercised options and sold 3,142 Monopar Therapeutics (MNPR) shares under a trading plan.
Stock Titan ·
- Monopar Therapeutics (MNPR) director sells shares under a May 27 trading plan.
Stock Titan ·
- Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
Yahoo Finance ·
- Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
Yahoo Finance ·
- Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Yahoo Finance ·
- Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
Yahoo Finance ·
Monopar Therapeutics key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | – | – |
| Net income | -$13.7M | -$15.6M | -$8.4M | -$10.5M |
| Total assets (year end) | $140.7M | $60.3M | $7.3M | $13.2M |
| Cash and equivalents (year end) | $61.8M | $45.8M | $7.3M | $8.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Monopar Therapeutics
- Ticker
- MNPR (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Wilmette, IL
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1645469
Frequently asked questions
What exchange is Monopar Therapeutics listed on?
Monopar Therapeutics trades on the Nasdaq under the ticker symbol MNPR.
What industry is Monopar Therapeutics in?
Monopar Therapeutics is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Monopar Therapeutics headquartered?
Monopar Therapeutics's business address on file with the SEC is in Wilmette, IL.
When does Monopar Therapeutics's fiscal year end?
Monopar Therapeutics's fiscal year ends on December 31.
How much revenue did Monopar Therapeutics report?
Monopar Therapeutics reported $0 in revenue for calendar year 2025, according to its SEC filings.